ESR1 and breast cancer: Specifically, we consider only biologically relevant configurations of the ER+ breast cancer cell baseline where 12 nodes representing biochemical components involved in signaling pathways are set to a particular state and the drug Alpelisib, i.e., an PI3K inhibitor, is active35.